https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-10 / JOP 2012 Jan;13(1):45-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-10 / JOP 2012 Jan;13(1):45-532012-01-10 00:00:002012-01-10 00:00:00Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Methods Mol. Biol. 2012;797:177-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-30 / Leuk. Res. 2012 May;36(5):634-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-30 / Leuk. Res. 2012 May;36(5):634-452011-11-30 00:00:002011-11-30 00:00:00Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-642011-11-15 00:00:002011-11-15 00:00:00Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:718710
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:7187102011-10-26 00:00:002019-02-15 09:21:34Safety and clinical usage of newcastle disease virus in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-982011-10-04 00:00:002021-11-15 16:58:12Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-08-24 / Intervirology 2012;55(4):276-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-08-24 / Intervirology 2012;55(4):276-862011-08-24 00:00:002019-02-15 09:21:38Apoptin enhances the oncolytic properties of Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)2011-06-06 11:53:442019-07-17 11:54:11Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-832011-05-30 00:00:002019-02-15 09:22:49Oncolytic viruses for the treatment of neuroendocrine tumors
